SIGA Technologies Inc. · NASDAQ:SIGA

SIGA Technologies — Investor Presentation (November 2026)

18 slides from SIGA Technologies's investor presentation, November 2026

  1. Slide 1: Company Overview: A Leader in Global Health & Infectious Diseases

    Company Overview A Leader in Global Health & Infectious Diseases

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements 2

  3. Slide 3: Contents

    Contents 1 About SIGA 2 The Smallpox Threat 3 TPOXX®: A Differentiated Product 4 Financial Summary

  4. Slide 4: SIGA At A Glance

    SIGA At A Glance TPOXX(1) 30+ Countries Strong Expertise Robust Balance Sheet A Foundational Franchise Where Products Infectious Disease, Health Disciplined & Trusted Treatment Have Been Sold Security, and Government Cash Management for Smallpox Contracting Who We Are Strategic Priorities SIGA is a

  5. Slide 5: SIGA is a Leader in Global Health Security

    SIGA is a Leader in Global Health Security Fully Integrated Infectious Disease Capabilities Foundation for Continued Attractive Growth • Commercial-stage pharmaceutical company operating within • Opportunities for TPOXX expansion (post-exposure prophylaxis infectious disease and health security ”PEP

  6. Slide 6: SIGA's Path to Maximize Shareholder Value

    SIGA’s Path to Maximize Shareholder Value External Trends ▪ Greater awareness of the need for preparedness ▪ Increased vulnerability to smallpox Government Relationships ▪ Higher risk of smallpox outbreaks ▪ Long-standing collaboration Core Capabilities with key U.S. government agencies ▪ More than

  7. Slide 7: The Smallpox Threat

    The Smallpox Threat

  8. Slide 8: Smallpox: Historic Milestones

    Smallpox: Historic Milestones Highly contagious and fatal disease in susceptible population 2017 2018 2021 2022 2024 2024 Canadian researchers U.S. FDA Health Canada EMA and MHRA (UK) U.S. Bipartisan Commission Japan’s PDMA approves synthesize horsepox, a approves approves approve Tecovirimat- on Bi

  9. Slide 9: Smallpox Remains a Significant Threat Today

    Smallpox Remains a Significant Threat Today Current geopolitical environment heightens the need for vigilance More than Smallpox can spread The ongoing geopolitical Smallpox globally before issues and advancements continues to 30% The Growing pose a serious global threat. Historic 300M symptoms appe

  10. Slide 10: TPOXX: A Differentiated Product

    TPOXX: A Differentiated Product

  11. Slide 11: TPOXX: The Essentials

    TPOXX: The Essentials A highly targeted antiviral treatment against orthopoxviruses, including smallpox As the first FDA-approved antiviral treatment for smallpox, TPOXX was among the first therapies delivered to the U.S. SNS under Project BioShield. TPOXX’s was developed in partnership with, and wi

  12. Slide 12: TPOXX is a Clinically Differentiated Medical Countermeasure

    TPOXX is a Clinically Differentiated Medical Countermeasure Antivirals Vaccines TPOXX ACAM2000® TEMBEXA® IMVANEX/IMVAMUNE/ Tecovirimat SIGA, TEPOXX (plus other replicating (CMX001/brincidofovir) JYNNEOS® (MVA-BN®) (ST-246/tecovirimat) vaccinia vaccine) ▪ First FDA-approved drug for the ▪ FDA-approve

  13. Slide 13: Track-Record of >$1B Successful Long-Standing Government Contracts for TPOXX

    Demonstrated Track-Record of >$1B Successful Long-Standing Government Contracts for TPOXX 2011 TPOXX CONTRACT 2018 TPOXX CONTRACT Procurement Duration 2011 - 2018 2018 - 2026 U.S. Biomedical Advanced Research U.S. Biomedical Advanced Research Key Agency Involved and Development Authority (BARDA) and

  14. Slide 14: TPOXX as a PEP Aims to Expand Health Benefits When Exposed to Smallpox

    TPOXX as a PEP Aims to Expand Health Benefits When Exposed to Smallpox Totality of data suggests administration is optimal as early as possible or as post-exposure prophylaxis Antiviral Post-Exposure Prophylaxis Antiviral Treatment for Active Infections Vaccines Window Optimally within 3 days but no

  15. Slide 15: Financial Summary

    Financial Summary

  16. Slide 16: Strong Financial Performance Over Time

    Strong Financial Performance Over Time Balance Sheet at Product Revenues ($mm) Pre-tax Operating Income ($mm) September 30, 2026 $127 $131 $133 $85 $89 $84 ▪ Cash balance of $116 $70 $116 million $87 $88 $43 $24 ▪ No debt 2020 2021 2022 2023 2024 2025 2020 2021 2022 2023 2024 2025 Capital Management

  17. Slide 17: Our Financial Journey: 2020 to 2025

    Our Financial Journey: 2020 to 2025 2020 2021 2022 2023 2024 2025 1 U.S. Government Orders ($ in millions) Product Revenues ▪ $546 mm of TPOXX ordered for the SNS Oral TPOXX ▪ $30 mm of oral TPOXX ordered by the Department $113 $113 $7 $110 $84 $53 (U.S. Government) of Defense Oral TPOXX $2 $13 $71

  18. Slide 18: Key Takeaways

    Key Takeaways Leveraging Building on Driving Organic Expanding Maintaining a Infectious Disease Successful Growth Platform with Robust Foundation TPOXX Franchise Initiatives Inorganic Growth Balance Sheet Leading health security Proven track record of Multiple organic growth Attractive opportunities

SIGA Technologies — Investor Presentation (November 2026) on 6ix